Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

Selective occlusion of tumor vasculature was tested as a therapy for solid tumors in a mouse model. The formation of blood clots (thrombosis) within the tumor vessels was initiated by targeting the cell surface domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker on tumor vascular endothelial cells. This truncated form of tissue factor (tTF) had limited ability to initiate thrombosis when free in the circulation, but became an effective and selective thrombogen when targeted to tumor endothelial cells. Intravenous administration of the antibody-tTF complex to mice with large neuroblastomas resulted in complete tumor regressions in 38 percent of the mice.

[1]  K. Mann,et al.  Role of the membrane surface in the activation of human coagulation factor X. , 1992, The Journal of biological chemistry.

[2]  G. Thurston,et al.  Tumour-derived factors which induce endothelial tissue factor and enhance the procoagulant response to TNF. , 1991, International journal of radiation biology.

[3]  M. Greaves,et al.  Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[4]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Y. Nemerson,et al.  Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. , 1986, Biochemistry.

[6]  J. Folkman,et al.  The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.

[7]  Harold E. Dvorak,et al.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.

[8]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[9]  F. Burrows,et al.  Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[11]  A. Rehemtulla,et al.  Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. , 1991, The Journal of biological chemistry.

[12]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Zardi,et al.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.

[14]  F. Burrows,et al.  Vascular targeting--a new approach to the therapy of solid tumors. , 1994, Pharmacology & therapeutics.

[15]  K. Jellinger,et al.  Increased levels of type VIII collagen in human brain tumours compared to normal brain tissue and non-neoplastic cerebral disorders. , 1991, British Journal of Cancer.

[16]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[17]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[18]  O. Fodstad,et al.  Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. , 1988, Cancer research.

[19]  W. Kisiel,et al.  Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. , 1993, Journal of the National Cancer Institute.